A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen
A study to assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in terms of efficacy, safety and tolerability
This study is designed to investigate the efficacy, safety, tolerability of a new drug, MEDI4736 (Durvalumab), in patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer. MEDI4736 will be investigated in patients who have received at least two prior treatment regimens including one platinum-based chemotherapy
Inclusion Criteria:
Exclusion Criteria:
Akashi-shi, 673-8558, Japan
Habikino-shi, 583-8588, Japan
Hidaka-shi, 350-1298, Japan
Hirakata-shi, 573-1191, Japan
Kitaadachi-gun, 362-0806, Japan
Kurume-shi, 830-0011, Japan
Shinjuku-ku, 160-0023, Japan
Sunto-gun, 411-8777, Japan
Ube-shi, 755-0241, Japan
Hwasun-gun, 58128, South Korea
Muang, 50200, Thailand